Perrigo : FDA Oks Store Brand OTC Equivalent Of Imodium Multi-Symptom Relief

Perrigo Company plc (PRGO) said that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg).

The product will be packaged and marketed as store brands or retailer 'own label' brands and will provide consumers with a high-quality, value alternative to the national brand.

Perrigo noted that it is finalizing plans to launch its wholly owned store brand loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, in the fourth quarter of 2018.

Imodium Multi-Symptom Relief is indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Retail sales for the last 12 months were approximately $62 million as measured by IRI.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT